Enhancing Cell Collection for Next-Gen Therapies

The best possible starting material is critical to providing the best outcome

15

October

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

Maintaining the quality and consistency of starting material is one of the most critical challenges facing cell therapy developers, especially for therapies like CAR-T and stem cell-based treatments where success begins at collection.

Join us for this free webinar to hear from a seasoned apheresis physician and a leading therapy manufacturer as they share their collaborative approach—starting with the end in mind. Learn how they align on treatment goals, communicate effectively, and use real-world cell collection data to optimize outcomes.

Hosted by Terumo Blood and Cell Technologies, this session offers expert insights on how precision in collection can help bring next-generation therapies within reach.

Learning Objectives:

  • Understand the impact of starting material quality
  • Explore effective collaboration strategies
  • Learn how to leverage real-world cell collection data
  • Gain practical insights from both clinical and manufacturing perspectives

Speakers

Select a speaker to learn more

Back
Kate Rochlin, PhD
COO, IN8Bio

Dr. Kate Rochlin has served as IN8bio’s Chief Operating Officer since December 2021 and previously as their VP, Operations and Innovation. She has 19+ years of expertise in strategic company development & operations, IP, CMC, and Clinical manufacturing of advanced therapies. She was previously the Chief Business Officer at Curadigm, a Cambridge-based spin-out of Nanobiotix focused on RNA therapeutic bioavailability. Prior, Dr. Rochlin co-founded and served as CSO at Immunovent in New York City. Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, researched at Sloan Kettering Institute, and a BA from the University of Pennsylvania.

Next speaker
Back
Erin Goodhue, DO, MPH
Associate Director, Transfusion and Apheresis Services

Dr. Erin (Meyer) Goodhue, DO, MPH, is Director of Transfusion and Apheresis Services at The Ohio State University Wexner Medical Center. She brings 20+ years of leadership across academic medicine, pediatric care, industry, and global research. Prior to her current role, Dr. Goodhue served as Director of Global Clinical Research at Terumo BCT and held clinical leadership roles at Nationwide Children’s Hospital and the American Red Cross. She earned her DO from the University of New England, an MPH from Dartmouth, and completed faculty appointments at Harvard, Emory, and Dartmouth.

Next speaker

Enquiry